Abstract

In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy for partial-onset seizures with or without secondary generalization in patients with epilepsy. It was approved by the FDA as an adjunctive therapy for partial-onset seizures in October 2008.

Author affiliations

1. Emilio Perucca is at the Department of Internal Medicine and Therapeutics and Institute of Neurology, IRCCS C Mondino Foundation, University of Pavia, Italy.
   Email: perucca@unipv.it
2. Uma Yasothan and Gilbert Clincke are at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.
   Email: UYasothan@de.imshealth.com
3. Peter Kirkpatrick is at Nature Reviews Drug Discovery.
   Email: p.kirkpatrick@nature.com

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.